469 related articles for article (PubMed ID: 31970590)
1. Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches.
Menyhárt O; Győrffy B
Cancer Metastasis Rev; 2020 Mar; 39(1):211-233. PubMed ID: 31970590
[TBL] [Abstract][Full Text] [Related]
2. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
[TBL] [Abstract][Full Text] [Related]
3. Medulloblastoma: an Old Diagnosis with New Promises.
Szalontay L; Khakoo Y
Curr Oncol Rep; 2020 Jul; 22(9):90. PubMed ID: 32643099
[TBL] [Abstract][Full Text] [Related]
4. Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas.
Menyhárt O; Győrffy B
Ann Clin Transl Neurol; 2019 May; 6(5):990-1005. PubMed ID: 31139698
[TBL] [Abstract][Full Text] [Related]
5. Updates on Management of Adult Medulloblastoma.
Majd N; Penas-Prado M
Curr Treat Options Oncol; 2019 Jun; 20(8):64. PubMed ID: 31236711
[TBL] [Abstract][Full Text] [Related]
6. Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas.
Menyhárt O; Giangaspero F; Győrffy B
J Hematol Oncol; 2019 Mar; 12(1):29. PubMed ID: 30876441
[TBL] [Abstract][Full Text] [Related]
7. [Subgroup-specific genomic alterations and potential prognostic biomarkers in childhood medulloblastomas].
Menyhárt O; Szabó A; Garami M; Gyõrffy B
Magy Onkol; 2019 Dec; 63(4):331-345. PubMed ID: 31821388
[TBL] [Abstract][Full Text] [Related]
8. Signaling pathway deregulation and molecular alterations across pediatric medulloblastomas.
Lhermitte B; Blandin AF; Coca A; Guerin E; Durand A; Entz-Werlé N
Neurochirurgie; 2021 Feb; 67(1):39-45. PubMed ID: 29776650
[TBL] [Abstract][Full Text] [Related]
9. Molecular Subgrouping of Medulloblastoma: Impact Upon Research and Clinical Practice.
Gupta T; Shirsat N; Jalali R
Curr Pediatr Rev; 2015; 11(2):106-19. PubMed ID: 26133181
[TBL] [Abstract][Full Text] [Related]
10. New Approaches in Targeted Therapy for Medulloblastoma in Children.
Maier H; Dalianis T; Kostopoulou ON
Anticancer Res; 2021 Apr; 41(4):1715-1726. PubMed ID: 33813375
[TBL] [Abstract][Full Text] [Related]
11. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.
Ramaswamy V; Remke M; Bouffet E; Bailey S; Clifford SC; Doz F; Kool M; Dufour C; Vassal G; Milde T; Witt O; von Hoff K; Pietsch T; Northcott PA; Gajjar A; Robinson GW; Padovani L; André N; Massimino M; Pizer B; Packer R; Rutkowski S; Pfister SM; Taylor MD; Pomeroy SL
Acta Neuropathol; 2016 Jun; 131(6):821-31. PubMed ID: 27040285
[TBL] [Abstract][Full Text] [Related]
12. Genetic Markers as Predictors for Response to Treatment and Possible Therapeutic Targets in Medulloblastoma.
Pérez-Pineda PL; Ortiz-Butrón R; Pérez-De Marcos JC; Hernández-Regino LM; Zapata-Tarrés MM; Torres-Espíndola LM
CNS Neurol Disord Drug Targets; 2023; 22(5):634-642. PubMed ID: 35579144
[TBL] [Abstract][Full Text] [Related]
13. Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets.
Marques RF; Moreno DA; da Silva L; Leal LF; de Paula FE; Santana I; Teixeira G; Saggioro F; Neder L; Junior CA; Mançano B; Reis RM
Front Immunol; 2023; 14():1062856. PubMed ID: 36825029
[TBL] [Abstract][Full Text] [Related]
14. Medulloblastoma: what is the role of molecular genetics?
Entz-Werle N; Carli ED; Ducassou S; Legrain M; Grill J; Dufour C
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1169-81. PubMed ID: 18588461
[TBL] [Abstract][Full Text] [Related]
15. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial.
Clifford SC; Lannering B; Schwalbe EC; Hicks D; O'Toole K; Nicholson SL; Goschzik T; Zur Mühlen A; Figarella-Branger D; Doz F; Rutkowski S; Gustafsson G; Pietsch T;
Oncotarget; 2015 Nov; 6(36):38827-39. PubMed ID: 26420814
[TBL] [Abstract][Full Text] [Related]
16. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
[TBL] [Abstract][Full Text] [Related]
17. Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
Zhao F; Ohgaki H; Xu L; Giangaspero F; Li C; Li P; Yang Z; Wang B; Wang X; Wang Z; Ai L; Zhang J; Luo L; Liu P
Neuro Oncol; 2016 Jul; 18(7):982-90. PubMed ID: 27106407
[TBL] [Abstract][Full Text] [Related]
18. Molecular Classification of Medulloblastoma.
Kijima N; Kanemura Y
Neurol Med Chir (Tokyo); 2016 Nov; 56(11):687-697. PubMed ID: 27238212
[TBL] [Abstract][Full Text] [Related]
19. Medulloblastoma: From Myth to Molecular.
Ramaswamy V; Taylor MD
J Clin Oncol; 2017 Jul; 35(21):2355-2363. PubMed ID: 28640708
[TBL] [Abstract][Full Text] [Related]
20. Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.
Goschzik T; Zur Muehlen A; Doerner E; Waha A; Friedrich C; Hau P; Pietsch T
J Neuropathol Exp Neurol; 2021 Apr; 80(5):419-430. PubMed ID: 33870422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
